We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Halozyme Therapeutics announced argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019.